Table 1.
Patients’ clinical and demographic characteristics
| Characteristics | n (%) | n (%) |
|---|---|---|
| Patients/PIPAC | Patients (n = 42) | PIPAC (n = 74) |
| 1 PIPAC procedure | 17 (40.4%) | |
| 2 PIPAC procedures | 18 (42.9%) | |
| ≥3 PIPAC procedures | 7 (16.7%) | |
| Drug doses used for PIPAC | ||
| Cisplatin 7.5 + doxorubicin 1.5 | – | 29 (39%) |
| Cisplatin 10.5 + doxorubicin 2.1 | – | 45 (61%) |
| Age, years | 60.5 (49–68)a | |
| Sex | ||
| Male | 15 (35.7%) | |
| Female | 27 (64.3%) | |
| CRS ± HIPEC | 11 (26%) | |
| PCI | 16 (8–26)a | |
| Ascites | ||
| First PIPAC | 20; 499 mL (0–6800)b | |
| Second PIPAC | 15;999 mL (0–7800)b | |
| Postoperative stay | 5 (±2)c | |
| Organ resection | ||
| Adnexectomy | 7 (17%) | |
| Major complications | ||
| CTCAE (III, IV) | 2 (2%) | |
| Clavien Dindo >3a | 0 | |
| Mortality | ||
| 30-day mortality | 0 | |
| 90-day mortality | 7 (17%) | |
PIPAC pressurized intraperitoneal aerosol chemotherapy, CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy, PCI Peritoneal Cancer Index, min minimum, max maximum, CTCAE Common Terminology Criteria for Adverse Events
aMedian (p25–p75)
bn; median (min–max)
cMean (SD)